Veru Inc. has released a presentation detailing its ongoing focus on cardiometabolic diseases, highlighting advancements in its drug candidate pipeline. The company is developing a combination therapy of Enobosarm, an oral selective androgen receptor modulator (SARM), and a GLP-1 receptor agonist aimed at improving weight loss outcomes while preserving muscle mass and function in patients undergoing GLP-1-based weight reduction therapy. The Phase 2 QUALITY Study for this program has been completed, with a Phase 2b PLATEAU study scheduled to begin patient enrollment in early 2026. The presentation notes a significant increase in GLP-1 receptor agonist use among American adults, with approximately 43 million users in 2025, up from 20 million in 2024. It also addresses challenges associated with GLP-1 therapies, including the nonselective loss of both muscle and fat, and the high incidence of patients reaching a weight loss plateau. Veru is also advancing Sabizabulin, an oral microtubule disruptor with anti-inflammatory properties, for the potential treatment of atherosclerosis in patients with stable coronary artery disease, with a Phase 2 trial planned. You can access the full presentation through the link below.